News and Events

Latest News

10 Jun 2021
Oxford Immunotec Presents Data on the Use of T-SPOT®.TB Test in Children over the Age of 2 to The Korean Society of Pediatric Infectious Diseases



READ MORE

29 Apr 2021
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups



READ MORE

27 Apr 2021
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses

READ MORE

04 Mar 2021
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID , a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

READ MORE

04 Mar 2021
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID , a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

READ MORE

4 Feb 2021
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses


READ MORE


Events

Moving Beyond the Tuberculin Skin Test (TST) (also known as the Mantoux Test)
Find out why this century-old test is no longer highly effective for the needs of the 21st century. Learn what the other options for TB screening are and the pros and cons of these different tests.





WATCH REPLAY
Expert Series: What is the Borderline?
(Part 1)
Dr. Juzar Ali discusses the T-SPOT®.TB test’s Borderline result category and its clinical utility in helping to reduce the risk of misclassifying patients whose results are around the test’s established cut-offs for Positive or Negative. This video discusses the utility and significance of the T-SPOT.TB test’s Borderline result category.


WATCH REPLAY
Expert Series: What is the Borderline? Case Studies (Part 2)
Dr. Juzar Ali presents three patient case studies to illustrate the importance of the T-SPOT®.TB test’s Borderline result category in clinical scenarios.






WATCH REPLAY
Diagnosing TB in the Immunocompromised: What’s New?
The risk of progression from Latent TB infection (LTBI) to active TB is higher amongst immunocompromised patients — who are they? Webinar covers an update on TB testing methods amongst immunocompromised patients and the clinical utility of IGRAs in this patient population group.


WATCH REPLAY
Expert Series: FAQS to Diagnosing TB in the Immunocompromised (Part 1)
LTBI Testing Methodologies: Dr Roy Chemaly answers Frequently Asked Questions (FAQs) about diagnosing Latent TB infection (LTBI) in immunocompromised patient populations.





WATCH REPLAY
Expert Series: FAQS to Diagnosing TB in the Immunocompromised (Part 2)
Immunocompromised Patient Population: Dr. Roy Chemaly answers Frequently Asked Questions (FAQs) about diagnosing Latent TB infection (LTBI) in immunocompromised patient populations.





WATCH REPLAY